Treatment with tuspetinib in combination with Venclexta and Vidaza in newly diagnosed acute myeloid leukemia showed safety ...

The following is a summary of “Karyotype evolution of myelodysplastic syndrome and acute myeloid leukemia with TP53 mutations,” published in the February 2025 issue of the International Journal of ...

The CRISTALLO trial showed that venetoclax plus obinutuzumab achieved high minimal residual disease negativity as a frontline ...

Aptose Biosciences advances its Phase 1/2 TUSCANY trial, escalating tuspetinib dosing after a favorable safety review. Enrollment continues across U.S. sites.

TP53 mutations are found in approximately half of all cancers. Our co-founder, Dr. Arnold Levine, established the field of p53 biology when he discovered the p53 protein in 1979. Bringing together ...

Lung cancer cases are increasing in people who have never smoked, especially in women, a new study by the World Health ...

In the subgroup with 17p deletion or TP53 mutation, zanubrutinib outperformed others with the most favorable HR (0.52) and the highest SUCRA value of 97%.

While genetic screening is not a magic bullet, it has the potential to change the landscape of childhood cancer care in India ...

By analyzing ERBB2 mRNA expression data, researchers identified a group of HER2-negative patients with poor outcomes and potential markers of treatment resistance.

Aptose Biosciences (NASDAQ:APTO;TSX:APS), a clinical-stage oncology stock, achieved positive safety and response results from ...

In January 2025, Aptose announced the initiation of the TUSCANY trial and dosing in the first cohort of newly-diagnosed AML patients with the lowest starting dose (40 mg) of TUS as part of the ...